Compare Abeona Therapeutics Inc (ABEO) vs Linde PLC (LIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Linde PLC — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Linde PLC trades at $529.65 (market cap $248.85B). The key difference: Linde PLC is far larger — about 666.6× Abeona Therapeutics Inc's market cap, and Linde PLC pays a 1.19% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | LIN | |
|---|---|---|
Market Cap | $373.32M | $248.85B |
Sector | Health | Basic Materials |
52-Week High | $7.23 | $546.64 |
52-Week Low | $4.17 | $389.38 |
Enterprise Value | $228.22M | $271.21B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Linde (LIN) trades at $540.52, down 1.12% on the day, with a bullish technical outlook supported by moving averages and key resistance at $546. The company reported strong Q1 2026 EPS of $4.33, beating estimates, and maintains robust profitability with a 20.44% net income margin. Recent news highlights sustainability leadership and strategic growth, while cash flow remains positive despite projected 2026 outflows.
Outlook remains positive with 85.7% analyst buy ratings and a $570.80 consensus price target, suggesting 5.6% upside. Risks include rising debt-to-asset ratio (31.63% in 2025) and valuation concerns (P/E 35.84). The stock offers a dividend yield of approximately 0.3% with consistent shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
